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Abstract
Triple Negative Breast Cancer (TNBC) is a difficult type of cancer to treat
because it is negative for progesterone, estrogen, and HER-2 receptors. Because TNBC is
negative for these three receptors, it does not respond to normal hormonal therapies. The
purpose of my experiment is to see if different cannabinoids, compounds from the
Cannabis plants, could be used as alternative treatment options. These experiments
employed three different cannabinoids: ajulemic acid, cannabidiol, and hemp oil. Cell
viability was measured after 72 hours of treatment using a MTT assay. The results
showed that the three cannabinoids could be used to effectively destroy the TNBC cells.
We used this data to calculate the median lethal dose (LD-50), the concentration of the
cannabinoid that can be given to destroy half of the cells. Our data suggest, cannabinoids
could potentially be used as an alternative treatment for TNBC. However, much more
testing would need to be done before it could be confirmed as a viable treatment option.

Introduction
Many people today use Cannabis for medicinal purposes. Many cancer patients
use cannabis to help with the pain and the nausea produced as a side effect of
chemotherapy. There has been research that shows Cannabis' potential to not only help
with symptoms of chemotherapy but to also help prevent angiogenesis and metastasis of
cancerous tumor cells (McCarthy). A major issue that surrounds the use of cannabis is the
psychoactive effect that follows its usage. To get around this issue, the cannabinoids that
were used for the experiment do not produce these psychoactive effects. We want to
know whether these cannabinoids are effective in preventing the growth of breast cancer
cells.
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Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC) is so called because it is negative for the
three receptors that normally fuel breast cancer growth. TNBC is negative for the
estrogen receptor (ER), the progesterone receptor (PR), and the hormone epidermal
growth factor receptor 2/neu (HER-2) (Fig. 1) (Crown). A lack of the three receptors
means the growth of the cancer is not supported by the hormones estrogen or
progesterone or by the presence of an abundance ofHER-2 (Crown). Many breast cancer
treatments will target any of these three receptors via hormonal therapy. However,
because TNBC does not contain these receptors, this particular type of breast cancer is
difficult to treat. Earlier stages of TNBC may respond well to chemotherapy, but it is not
always effective. TNBC is typically treated with a combination of surgery, radiation
therapy, and chemotherapy (McCarthy). However, these treatments cause the person to
be very sick and weak and there is still a high chance that the cancer will return after
treatment.
TRIPLE NEGATIVE CANCER CELL

Figure 1: There are no receptor sites on the enzyme that the specific shapes ofER, PR, and HER-2 will be able to bind
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About 10-20% ofbreast cancers in the United States are Triple Negative. This
particular type is more likely to affect younger women (between the age of 40 or 50),
African American women, Hispanic women, and individuals with a BRCA 1 gene
mutation (Amirikia). TNBC tends to be more aggressive than other types of breast
cancers. TNBC is more likely to spread beyond the breast and more likely to return after
treatment. These risks are greatest within the first few years of treatment. Typically, if the
cancer has not recurred after about five years, the likelihood of the cancer returning is
much smaller (Liedtke). Furthermore, the five-year survival rates for TNBC are typically
lower than other breast cancers. A study conducted in 2007 with more than 50,000
women in all stages of breast cancer showed that 77% of women with TNBC survived at
least five years compared to the 93% of women that survived with other types of breast
cancer. Also, TNBC cells typically had a higher grade than other types of breast cancer.
On a scale of one to three, TNBC is typically a grade three. A higher grade means there
are less cancer cells that resemble normal, healthy breast cells in their appearance and
growth patterns (Boyle).
A typical mutation that can cause Triple Negative Breast Cancer is the mutation
in the tumor suppressor gene BRCAI. A normal BRCAl gene would prevent the
development of cancers. The BRCAl gene plays a role in repairing damaged doublestranded DNA and controlling cell proliferation and cell differentiation. A woman with a
mutation at the BRCAl gene has an increased risk of developing breast cancer. However,
a mutation in the BRCAI gene does not mean TNBC will develop; it will just increase
the risk. Furthermore, not all women who develop TNBC will have this specific
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mutation; there are other unknown factors that are contributors to developing TNBC as
well (Lindeman).
In order to raise the five-year survival rate, researchers have been trying to find
targeted therapies for TNBC. Three potential treatments are currently being developed. A
Poly-ADP-ribose polymerase (PARP) inhibitor is being developed to prevent the enzyme
PARP from repairing the DNA of breast cancer cells. PARPl acts on single stranded
DNA to repair it when breaks occur. IfPARPl is inhibited, there should be an increase in
breaks in the DNA. BRCAl is required to repair the DNA. However, the cells with
dysfunctional BRCAl will not be able to repair the DNA. Therefore, by inhibiting
PARPl, the cells with BRCAl dysfunction should become unstable and undergo
apoptosis, leaving behind the normal cells (McCarthy). Potentially, this could make
chemotherapy more effective at destroying the cancerous cells. Anti-angiogenic agents
are being developed to inhibit angiogenesis. Angiogenesis is the formation of new blood
vessels that must occur in tumors for them to receive oxygen and nutrients needed to
grow and spread. Drugs such as bevacizmnab (Avastin®) and sutinib (Sutent®) are being
developed to inhibit angiogenesis and cell growth. Furthermore, epidermal growth factor
receptor (EGFR) targeted therapies are being developed to prevent the overexpression of
the protein EGFR. An abundance of EGFR will encourage the growth of the cancer. If a
treatment can target EGFR, potentially the cell will be inhibited from
growing(McCarthy).
The cells used for the following experiment come from a Caucasian woman in her
early 50s. The TNBC cells, referred to as MDA-MB-231 for the experiment, are taken
from the patient's mammary gland/breast. The cells used were taken from an aneuploidy
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female, which means she contains an abnom1al number of chromosomes. The nonnal
chromosomes N8 and N15 are absent. Fmthermore, the epidermal growth factor (EGF)
and the transfom1ing growth factor alpha (TGF alpha) receptors are expressed in the cells
(lv!DA-lvfB-231 ATCC).

Cannabinoids
Cannabinoids are naturally occurring compounds found in the plant Cannabis
sativa. Cannabinoids exert their effects by interacting with the cannabinoid receptors,
CB 1 and CB2, located on the surface of the cells. CB 1 receptors are located in the central
nervous system (Howard). CB2 receptors are typically found in the immune system.
Cannabinoids in the brain typically affect the limbic system, which alters memory,
cognition, and psychomotor performance. Cannabinoids will also affect the mesolimbic
pathway, which affects the reward and pleasure responses and will also alter pain
perception (Howard). Since CB 1 receptors are mainly located in the central nervous
system, stimulation of these receptors produces a marijuana-like effect on the psyche and
circulation, while no such effect is seen by activated CB2 receptors (Howard). There are
many different subclasses of cannabinoids, the most well known being delta-9tetrahydrocannabinol

(~9 - THC

or THC) (Fig. 2). THC is the main psychoactive

ingredient in cannabis or marijuana. A higher concentration of THC is derived from the
leaves and the flowering parts of the cannabis plant (Adams).
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A·9·tetrahydrocannablnol (THC)
Figure 2: J\ tolerular structure of THC.

Cannabinoids are believed to have medicinal benefits in the treatment of cancer.
Cannabinoids have potential to cause antitumor effects by various mechanisms including:
induction of cell death, inhibition of cell growth, and inhibition of tumor angiogenesis
invasion and metastasis (Vaccani). The downside to using cannabis to help with the
cancer is that it causes the patient to be in a daze for an extended period of time. Three
alternative drugs that were used in this experiment were ajulemic acid, hemp oil, and
cannabidiol. These three cannabinoids are structurally similar to THC. All three of these
drugs have little to no THC present, thus there is no psychoactive effect.
Ajulemic Acid

Ajulemic acid (AJA) is a synthetic cannabinoid that is structurally similar to THC
(Fig. 3), but will not have the same psychoactive effects. They both act as analgesics and
anti-inflammatory agents (Recht, Salmonsen, et al.). Ajulemic acid also has potential to
be used as an antitumor agent. While CB 1 and CB2 receptor antagonists blocked the
effects of THC, only CB2 receptor antagonists blocked the effects of AJA. This means
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that AJA produces antitumor activity by acting at least partially through the CB2
receptors (Recht, Salmonsen, et al.).

B

A

THC· ll·OIC Add

Ajulemie Add
Figure 3: A) THC is responsible fo r the psyrhoaetive effects of cannabis. B) THC-11-ok add is the oxidized
l'onn ofTHC. C) Ajulemic Acid is a nonpsychoacthe synthetic derivative ofTHC-! !-oil' add.

Hemp Oil
Hemp oil has been extracted from the stalk and stems of the cannabis plant and
contains many different cannabinoid compounds. At these two areas of the plant, the
THC concentration is less than 0.6%. Hemp oil also contains natural oils, as in flavonoids
and turpenoids. Due to the extremely low concentration ofTHC, hemp oil does not have
any psychoactive effects but should produce the same medicinal benefits as THC and
AJA.

Cannabidiol
Cannabidiol (CBD) is present in the cannabis plant but has been purified (Fig. 4).
CBD is considered to be the most abundant cannabinoid. CBD is similar to AJA and
hemp oil in that it maintains the medicinal benefits while producing no psychoactive
effects. People exhibiting a wide variety of conditions have used CBD; these conditions
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include arthritis, epilepsy, MS, chronic pain, schizophrenia, and diabetes. CBD has
shown sedative, anti-epileptic, anti-dystonic, anti-emetic, and anti-inflammatory affects
on people with the previous conditions (Grotenhermen).

Figm·•· 4: Structure or Cannabidiol.

MT'T Cell Proliferation Assay

The MTT Assay was used to measure cell viability in cannabinoid treated and
untreated cells. MTT, more specifically yellow tetrazolium MTT (3-( 4, 5dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide), is a chemical that can be cleaved
by an enzymatic reaction that occurs in actively respiring mitochondria. A cell that is
alive will have respiring mitochondria that have active dehydrogenase enzymes. These
enzymes will cleave MTT and generate NADH or NADPH (American Type Culture

Collection). The products of this reaction will produce a purple precipitate (Fig. 5).
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Figure 5: MTT reduction in living cells forms formazan, which creates a purple precipitate.

The purple precipitate can be quantified by measuring the absorbance. If there are more
cells alive, there is a darker purple color throughout the liquid in the well. A darker
purple color will give a higher absorbance (about 550 nm), which indicates more viable
or live cells. An absorbance value that is lower than the control cells will typically be a
clear color indicating a reduction in the number of live cells (Fig. 6).

Figure 6: An example of an MTT Assay. The top row, which is more purple shows, shows that more cells

are still respiring. The bottom row, which is a clear color, shows that most ofthe cells are dead.

LD-50
A LD-50 is the median lethal dose that is required to kill half the cells of the
tested population. The LD-50 is useful to measure the short-term toxicity potential of a
material. LD-50 is typically used in the pharmaceutical field to describe the dosage of
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drug that may be given before becoming toxic. Generally, the smaller the LD-50 value,
the more toxic the chemical is. The higher the LD-50 value, the lower the toxicity
(Zbinden).
Materials

For the three experiments performed, all of them used similar methods with a few
differing variables. All three involved plating cells and performing the MTT assay on
each plate. The main differences amongst the experiments were the concentrations of
AJA, CBD, and hemp oil used and the numbers of cells used.
Plating Cells

This method requires a 30 mL flask ofthe MDA-MB-231 cells that have been
grown at least 24-48 hours beforehand. A sufficient amount of grown, living cells is
necessary for this experiment to preform properly. Also needed for this method is roughly
30 mL ofthe cell's medium, 10 mL of PBS (IX), and 3 mL oftrypsin. Also required is a
vacuum pressure pump to vacuum off the medium, an incubator at 37°C, a 48-well plate,
and an automatic pipet aid device that dispenses the liquid into the wells. In addition to
these large machines, a large amount of glass Pasteur pipettes and disposable 5, 10, and
25 mL glass pipettes are required. Finally, a hemacytometer is required to count the
average number of cells present in the flask.
MIT Assay

This method will use the cells that were previously plated and subsequently
treated with the different concentrations of AJA, CBD, and hemp oil. It requires about 25
mL of the MTT reagent that has been added to the medium. The MTT assay also requires
about 25 mL of dimethyl sulfoxide (DMSO). This method will also need a vacuum
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pressure pump, a automatic pipet aid device, the Belly Dancer shaker, and the Tecan
infinite M200 plate reader. In addition, a large amount of glass Pasteur pipettes and
disposable 5 and 10 mL glass pipettes are required.

Treating with Higher Concentrations
This experiment requires a 48-well plate and cells at a concentration of 3 x 10 4
cells/well. ajulemic acid, cannabidiol, and hemp oil will each have concentrations at 20,
40, and 60 )lM. Also required for the experiment is DMSO and ethanol (EtOH) that is
concentrated at 60 equivalents (eq). This experiment will also use the materials required
for plating cells and the MTT assay.

Treating with Lower Concentrations
The experimental setup for this experiment is almost exactly the same as the
above experiment, except the concentrations are decreased. The concentrations for AJA
are set at 5, 10, 15, and 20 )lM. The concentrations for both CBD and hemp oil are set at
5, 10, and 15 )lM. Furthermore, DMSO and ethanol are present at a concentration of 15
eq. This experiment will also use the materials required for plating cells and the MTT
assay.

Methods
Plating Cells
Before beginning the experiment, the trypsin and medium must be pre-warmed
for at least fifteen minutes. Using the 30 mL flask of MD A-MB-231 cells that were
grown in the 37°C incubator for a period of time, vacuum off the media in the flask.
Make sure not to disturb the cells that are stuck to the back of the flask by positioning the
glass micropipette towards the front comer of the flask. After vacuuming off the media,
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add 10 mL ofPBS (IX) to the front ofthe flask. Rinse the flask gently with the PBS by
lightly tilting the flask on its back and swishing the liquid around. Then vacuum off the
PBS while making sure not to disturb the cells on the back ofthe flask. Following this
step, add 3 mL of the warmed trypsin to the flask. Place the flask with the trypsin into the
incubator at 37°C for a few minutes. The purpose of the trypsin is to loosen the cells from
the back of the flask, thus it is no longer necessary to worry about knocking the cells
loose. After incubating the cells, observe the cells in the flask under the microscope to
ensure the cells are no longer attached to the back of the flask. If there are cells not
moving around in the flask, then hit the flask slightly to knock the cells loose. Once all
the cells have been knocked loose, add 27 mL of the warmed medium to bring the total
volume in the flask back to 30 mL. Using a 25 mL pipette, mix the solution in the flask
multiple times. This is to ensure the cells are broken apart from each other (so that the
cells are not in large clumps). Place a small amount ofthis mixture into a vial(~ 20 !J.L).
Place 10 !J.L of the mixture on a hemacytometer. The hemacytometer will count the
average number of cells/mL in the flask. Place the hemacytometer underneath the
microscope and count the number of cells present in the square grids (there are eight
square grids). The eight numbers are then averaged and then multiplied by 10,000 (X x

10 4 cells/mL). In order to figure out how many milliliters of cells are needed, divide the
total number of cells needed by the amount of cells/mL previously calculated. The total
number of cells needed is 150 x 10 4 • To help determine the total number of cells needed,
there are 48 wells that are filled with 1 mL/well of the concentrated cells. To ensure there
is enough of the solution, multiply 3 x 10 4 by 50 (instead of 48) to obtain the number 150
x 10 4 cells total. To figure out the amount of media that must be added, subtract the

12

amount of milliliters of cells needed from 50. Put the milliliters of cells needed and the
milliliters of media needed into a separate flask. Mix the mixture thoroughly to ensure
that the cells are spread throughout. Place 1 mL of this mixture into each well on the
plate. Then move the plate back and forth a couple of times to prevent the cells from
being more confluent on the edges ofthe well. Finally, incubate the plate at 37°C for 24
hours to allow the cells to stick to the bottom of the wells. Make sure to replace the
amount of cells pulled out of the original flask with new media, so that new cells can be
grown. In order to determine the amount of cells and media needed use the following:
1. 50 X 3 x 10 4 = 150 x 10 4 cells total
2.

150
X

x

X

104

10 4

= X mL of cells

3. 50-XmLofcells=YmLofmedia

Determining the concentration of the cells
To determine the concentration of cells needed for the experiment, determine the
amount of cells and medium that should be added together to make the correct
concentration by using the plating cells protocol. Determining the concentration is a trial
and error type of test. Start with the concentrations of the experiment set at 3 x 10 4
cells/well and 4 x 10 4 cells/well. Make a 13 mL solution of the cells+ media, so that 1
mL of cells can be put into 12 wells. In order to determine the amount of cells and media
needed:
1. 13 X 3 x 10 4 = 39 x 10 4 total cells needed
2.

39 X 10 4
X xlO 4

= X mL of cells

3. 13-XmLofcells=YmLofmedia
4.

13 X 4 x 10 4 =52 x 10 4 total cells needed
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5.

52

X

10 4

X

X

10 4

= X mL of cells

6. 13- X mL of cells = Y mL of media
After adding 1 mL of 3 x 10 4 into all12 wells and 1 mL of 4 x 10 4 into all 12 wells,
incubate the plate for 24 hours. After incubating the plate, observe each well underneath
the microscope to ensure there is no contamination and equally grown cells. Then
vacuum off the media in each well (one row at a time) and add 1 mL of the cannabinoid
treatments to the wells. The cells at the concentration of 4 x 10 4 will be treated with
40

~M

ofCBD, 20

~M

ofhemp oil, and 40

~M

ofhemp oil. The cells at the

concentration of 3 x 10 4 will be treated with 20, 40, and 60 ~M of AJA. Each treatment
will be placed in three wells. Also, each concentration of cells will have three wells of
untreated, plain media. The 48-well plate will be incubated for 48 hours followed by a
MTT assay to measure the effects of the different concentrations.

Treating with Higher Concentrations
The MDA-MB-231 cells with a concentration of 3 x 10 4 are treated with the
cannabinoids after the cells have been plated onto a 48-well plate and incubated for 24
hours. Each well will receive 1 mL of the treatment after the solution in the wells has
been vacuumed off. It is necessary to observe each well under the microscope to ensure
the cells in each well look similar and normal. One treatment will be placed into four
different wells, thus at least 4 mL of the treatment will need to be made. The treatments
that will be used for this experiment are as follows: untreated, 60 eq ofDMSO, 60 eq of
ethanol, 20, 40, and 60

~M

of AJA, CBD, and hemp oil. In order to make AJA, CBD, and

hemp oil stock solutions, use the following:
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Using a small vial, add 10 )lL of 100 mM AJA stock solution to 90 )lL ofDMSO
to make a 10 mM stock solution. Make the hemp oil and CBD stock solution the same
way as the AJA stock solution. The only difference is the CBD stock solution will be
dissolved in 90 )lL of ethanol (instead ofDMSO).
In order to make the treatments (using 10 mM stock solutions of AJA, CBD, and
hemp oil and making 5 mL ofthe treatments), use the standard equation, M 1 V1 = M2 V2 :
(20 )lM ofcannabinoid)(5000 )lL)= (10,000 )lM of stock solution)(X )lL)= 10 )lL
(40 )lM of cannabinoid)(5000 )lL)= (10,000 )lM of stock solution)(X )lL)= 20 )lL
(60 )lM of cannabinoid)(5000 )lL)= (10,000 )lM of stock solution)(X )lL)= 30 )lL
Add 5 mL of media to 12 different vials that have been labeled for each treatment.
Then, using a micropipette, take 10, 20, or 30 )lL of media out of the 5 mL vials. Then
replace the same amount of microliters taken out with each specific cannabinoid. Once
each treatment has been properly added to each well, incubate the plate for 48 hours.
After this period of time, an MTT assay is performed and the data is recorded.

Treating with Lower Concentrations
The method for treating the cells with lower concentration is the same as treating
the cell with higher concentration. The only difference is the concentration of
cannabinoids used on the cells. The purpose of treating the cells with a lower
concentration of cannabinoids is to determine the LD-50. The treatments that will be used
for this experiment are as follows: untreated, 15 eq ofDMSO, 15 eq of ethanol, 5, 10, and
15 )lM of CBD and hemp oil, 5, 10, 15, and 20 )lM of AJA. The amount of stock solution
added to the 5 mL vials is as follows:
(5 )lM of cannabinoid)(5000 )lL)= (10,000 )lM of stock solution)(X )lL)= 2.5 )lL
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(10 J!M ofcannabinoid)(5000 J!L)= (10,000 J!M of stock solution)(X J!L)= 5 J!L
(15 J!M ofcannabinoid)(5000 J!L)= (10,000 J!M of stock solution)(X J!L)= 7.5 J!L
(20 J!M ofcannabinoid)(5000 J!L)= (10,000 J!M of stock solution)(X J!L)= 10 J!L
MI'T Assay

Before beginning the procedure, warm the MTT reagent + medium mixture
(49mL plain media+ 1 mL MTT reagent). This procedure will be performed on the 48well plate that was treated with the different concentrations of cannabinoids 48 hours
earlier. Every well should be observed underneath a microscope. This is to observe the
cells to make sure there is no contamination and they look normal. Using the vacuum
pressure pump and a glass micropipette, vacuum off the media in each well. Make sure
not to touch the micropipette to the bottom of the well, otherwise it could mess up the
results. After vacuuming off one row on the plate, add 0.5 mL of the MTT reagent+
medium to each well. Vacuum the wells one row at a time to prevent overexposure of the
cells to the environment. After all the wells are filled with 0.5 mL of the MTT reagent+
medium, incubate the plate at 37°C or one to two hours. After the plate has been properly
incubated, vacuum offthe media in the wells (one row at a time) and add 0.5 mL of
DMSO to each well. Once all the wells are filled, place the 48-well plate on The Belly
Dancer shaker for 10-20 minutes. Then place the plate into a Tecan Infinite M200 plate
reader. The wavelength in each well will be measured and these results will be graphed.

Results
Higher Concentration

After performing three separate trials on the MDA-MB-231 cells, it was
concluded that the higher concentrations of cannabinoids could successfully decrease the
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amount of cancerous cells that are alive. As can be deduced, all three of the cannabinoids
at concentrations of 40 and 60 J.lM have essentially killed all of the cells present in the
wells (Fig. 7). Ajulemic acid at a concentration of 20 J.lM appears to have the highest
percentage of cell viability amongst the treatments. The percentage, being at about 40%,
is still very low and is too high a concentration for us to be able to calculate the LD-50.
The CBD and hemp oil treatments at a concentration of 20 J.lM also have very low yields
of percent cell viability (less than 20%). As expected, the untreated cells and the cells
treated with 60 equivalents of either DMSO or ethanol have little to no effect on the cell
viability. The results of the experimentation with higher concentration of cannabinoids
showed that AJA, CBD, and hemp oil could effectively kill the MDA-MB-231 cells.
However, due to the low yield of percent cell viability, this is not an effective model to
determine a LD-50 value. To determine this, we would need to lower the concentrations.
Combined MTT MDA-MB-231
A.JA, CBD, Hemp Oil
9-22, 29; 10-6-14

Figure 7: Results of the MTT assay using the higher concentrations of cannabinoids.

Lower Concentrations
The concentrations were lowered in order to determine the LD-50 for AJA, CBD,
and hemp oil. A linear trend is observed when the concentration of each treatment is
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increased (Fig. 8). As the concentration of each treatment was increased, the percentage
of cell viability decreased. Furthermore, the untreated MDA-MB-231 cells and the cells
treated with 15 equivalents ofDMSO have a very high percent cell viability, which is
expected. An unexpected result that is observed is the consistent low percentage of cell
viability in the cells treated with 15 equivalents of ethanol. The most plausible reason for
this occurrence is because the ethanol seemed to be degraded. We concluded that the
reason the ethanol appeared to be killing the cells was because it had degraded. Another
unexpected result is that the cells treated with 5 J.l.M of AJA experienced a percent cell
viability that is higher than the percent cell viability for the untreated cells. The cause of
this is unknown but we do not believe that a very low concentration of AJA could
actually increase cell viability.
Combined MTT MDA-MB-231
AJA, CBD,Hemp Oil
10-20,31; 11-3,14-14
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Figure 8: A) Results ofthe MIT assay using the lower concentrations of cannabinoids. The line is
representative of where the LD-50 concentrations will be taken from. B) Color coated version of A.

LD-50

Using the data from figure 8, the LD-50 was determined. The data used to make
the graph in figure 8 was inserted into an excel spreadsheet, the different treatments were
averaged together, and made into a XY scatter plot. By using the trend line function, a
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line will be drawn through the data points producing an equation. By setting x=50, the
LD-50 is determined by solving for y. A rough estimate of the LD-50 can also be
determined by drawing a line through the graph at 50% cell viability (Fig. 8A). This will
not give an exact number, but is useful in the absence of excel. Based on the results, the
LD-50 in MDA-MB-231 cells for ajulemic acid is 27.9 )lM, cannabidiol is 4.3 )lM, and
hemp oil is 9.9 )lM.

Discussion and Conclusion
Purpose of DMSO and Ethanol
As discussed earlier, AJA and hemp oil are dissolved in DMSO to make the stock
solutions. CBD is dissolved in ethanol to make stock solution. Due to the presence of
DMSO and ethanol in each of the treatments, a negative control group is necessary. The
negative control group is to ensure that the DMSO or ethanol present in the original stock
solutions did not affect the viability ofMDA-MB-231 cells. We can determine the
DMSO and ethanol had no effect on the cells by observing the graphs in Figure 6. The
percent cell viability for 60 eq ofDMSO and ethanol is at or very near 100%. This shows
that DMSO and ethanol were not the cause in the decrease of cell viability. It was indeed
the work of the AJA, CBD, or hemp oil that caused the decrease in cell viability.
Determination from Concentrations
Based on the results from the different concentrations of cannabinoids, ajulemic
acid, cannabidiol, and hemp oil could be used to effectively kill the MDA-MB-231 cells
characteristic of Triple Negative Breast cancer. The higher concentrations (20, 40, and 60
J..lM) showed that AJA, CBD, and hemp oil could definitely kill the cells. The lower
concentrations (5, 10, 15, and 20 J..lM) provided the information needed to determine the
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concentration of AJA, CBD, and hemp oil that could be given to the MDA-MB-231 cells
in order to destroy half of the cells present. The two experiments in conjunction with one
another are able to provide a model to determine the effectiveness of the cannabinoids
and the required concentration of the cannabinoids.

Are Cannabinoids an effective treatment for Triple Negative Breast Cancer
Although this experiment was performed on a small scale, there is potential it
could also be effective on a larger scale. On a small scale, the different cannabinoids are
effective in treating Triple Negative Breast cancer cells. There are still many different
experiments that would need to be performed in order to determine the effectiveness of
the cannabinoids as an alternative treatment to chemotherapy and surgery. Before
becoming a viable treatment for Triple Negative Breast cancer, there would need to be
trials that observe the effects in model organism. There would also need to be a better
understanding of the pathway used by the treatments to assert its effects on the cells.
Potentially, though, AJA, CBD, and hemp oil could be used as alternative and less toxic
treatments for Triple Negative Breast cancer.
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